Compare Crispr Therapeutics AG (CRSP) vs ThredUp Inc (TDUP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs ThredUp Inc — how do they compare? Crispr Therapeutics AG trades at $51.28 (market cap $4.97B), while ThredUp Inc trades at $6.62 (market cap $817.47M). The key difference: Crispr Therapeutics AG is far larger — about 6.1× ThredUp Inc's market cap, and ThredUp Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | TDUP | |
|---|---|---|
Market Cap | $4.97B | $817.47M |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $12.08 |
52-Week Low | $44.34 | $3.11 |
Enterprise Value | $3.32B | $820.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
TDUP trades at $6.18, down 6.36% over 24 hours, with a mixed technical picture showing bullish moving averages but bearish oscillators. The company reported Q1 2026 revenue of $81.7 million, a 15% year-over-year increase, though net losses persist. Recent news highlights the launch of a peer-to-peer marketplace and AI-driven shopping features, signaling innovation efforts. Analyst sentiment remains positive with a consensus price target of $6.90 and 57% buy ratings.
The outlook hinges on TDUP's ability to leverage AI for cost reduction and growth in its resale platform, but risks include sustained profitability challenges and competitive pressures. With cash flow improving and debt levels manageable, the stock offers speculative upside if execution aligns with bullish analyst expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About ThredUp Inc
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →
